Subjects with impaired fasting glucose: evolution in a period of 6 years
E Leiva1, V Mujica2, R Orrego1
1Programa de Investigación de Excelencia Interdisciplinaria en Envejecimiento Saludable (PIEI-ES), Departamento de Bioquímica Clínica e Inmunohematología, Facultad de Ciencias de la Salud, Universidad de Talca, 3465548 Talca, Chile.
Aim:
To study the evolution of impaired fasting glucose (IFG), considering glucose and HbA1c levels and risk factors associated, in a period of 6 years.
Methods:
We studied 94 subjects with impaired fasting glucose (IFG) that were diagnosed in 2005 and followed up to 2012. Glucose and HbA1c levels were determined. A descriptive analysis of contingence charts was performed in order to study the evolution in the development of type-2 diabetes mellitus (T2DM).
Results:
Twenty-eight of ninety-four subjects became T2DM; 51/94 remained with IFG; and 20/94 presented normal fasting glucose. From the 28 diabetic subjects, 9 had already developed diabetes and were under treatment with oral hypoglycemic agents; 5 were diagnosed with plasma glucose < 126 mg/dL, but with HbA1c over 6.5%. In those who developed diabetes, 15/28 had a family history of T2DM in first relative degree. Also, diabetic subjects had a BMI significantly higher than nodiabetics (t test: P < 0.01). The individuals that in 2005 had the highest BMI are those who currently have diabetes.
Conclusion:
The IFG constitutes a condition of high risk of developing T2DM in a few years, especially over 110 mg/dL and in obesity patients.
More Related Videos
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
Related Concept Videos
Hyperglycemia
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type II Diabetes II: Pathophysiology
Diabetes: Symptoms, Diagnosis, and Complications
Type I Diabetes II: Pathophysiology
Type I Diabetes III: Clinical Manifestations
